Abstract
Antigens of infectious agents share amino acid sequences with human proteins. Such a peptide matching may lead to autoimmunity through crossreactivity phenomena following pathogen infection and/or immunotherapeutic approaches. In this framework, we analyzed as a model the primary sequence of human cytomegalovirus (HCMV) glycoprotein B (gB) protein and searched for viral peptide sequences shared with human proteins. We show that the HCMV antigen has a high peptide identity with a large number of human proteins at the penta-, hexa-, and heptapeptide level, with the viral versus human peptide overlap involving host proteins implicated in crucial processes such as embryonic development, spermatogenesis, spatial learning, and hippocampal plasticity, inter alia. This study might help understand the etiology of the pathologic sequela associated with HCMV (re)activation and, in addition, address scientific and clinical research toward the definition of antiviral therapeutics based on non-crossreactive viral sequences.
Keywords: Anti-HCMV immune response, autoimmune diseases, crossreactivity, HCMV glycoprotein B, human proteins, peptide sharing.
Current Drug Discovery Technologies
Title:Potential Crossreactivity of Human Immune Responses Against HCMV Glycoprotein B
Volume: 13 Issue: 1
Author(s): Guglielmo Lucchese and Darja Kanduc
Affiliation:
Keywords: Anti-HCMV immune response, autoimmune diseases, crossreactivity, HCMV glycoprotein B, human proteins, peptide sharing.
Abstract: Antigens of infectious agents share amino acid sequences with human proteins. Such a peptide matching may lead to autoimmunity through crossreactivity phenomena following pathogen infection and/or immunotherapeutic approaches. In this framework, we analyzed as a model the primary sequence of human cytomegalovirus (HCMV) glycoprotein B (gB) protein and searched for viral peptide sequences shared with human proteins. We show that the HCMV antigen has a high peptide identity with a large number of human proteins at the penta-, hexa-, and heptapeptide level, with the viral versus human peptide overlap involving host proteins implicated in crucial processes such as embryonic development, spermatogenesis, spatial learning, and hippocampal plasticity, inter alia. This study might help understand the etiology of the pathologic sequela associated with HCMV (re)activation and, in addition, address scientific and clinical research toward the definition of antiviral therapeutics based on non-crossreactive viral sequences.
Export Options
About this article
Cite this article as:
Lucchese Guglielmo and Kanduc Darja, Potential Crossreactivity of Human Immune Responses Against HCMV Glycoprotein B, Current Drug Discovery Technologies 2016; 13 (1) . https://dx.doi.org/10.2174/1568009616666160129100621
DOI https://dx.doi.org/10.2174/1568009616666160129100621 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interferon-Beta Therapy Monitoring in Multiple Sclerosis Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances in the Discovery of Novel HSP90 Inhibitors: An Update from 2014
Current Drug Targets Vitamin D Analogs in Cutaneous Malignancies
Current Pharmaceutical Design A QSAR Study on a Series of Indolin-2-Ones Acting as Non-Receptor Src Tyrosine Kinase Inhibitors
Letters in Drug Design & Discovery Multifaceted Mechanisms for Cell Survival and Drug Targeting in Chronic Myelogenous Leukemia
Current Cancer Drug Targets Direct Evidence on the Immune-Mediated Spontaneous Regression of Human Cancer: An Incentive for Pharmaceutical Companies to Develop a Novel Anti-Cancer Vaccine
Current Pharmaceutical Design Synthetic and Natural Immunomodulators Acting as Interferon Inducers
Current Pharmaceutical Design Mechanisms of Tumor Cell Necrosis
Current Pharmaceutical Design Iron Chelating Strategies in Systemic Metal Overload, Neurodegeneration and Cancer
Current Medicinal Chemistry Recent Progress in the Development of Histone Deacetylase Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets Multi-Target QSAR Approaches for Modeling Protein Inhibitors. Simultaneous Prediction of Activities Against Biomacromolecules Present in Gram-Negative Bacteria
Current Topics in Medicinal Chemistry Recent Progress in Chemically Modified siRNAs
Mini-Reviews in Medicinal Chemistry Developments of DNA-dependent Protein Kinase Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Critical Steps in Tissue Processing in Histopathology
Recent Patents on DNA & Gene Sequences Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Chem-Bioinformatics : Computational Modeling of TIBO Derivatives
Anti-Infective Agents in Medicinal Chemistry Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry Hypoxia Helps Glioma to Fight Therapy
Current Cancer Drug Targets Green Approaches for Cancers Management: An Effective Tool for Health Care
Anti-Cancer Agents in Medicinal Chemistry